COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
List view / Grid view
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells.
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
A statement from scientists has highlighted that improving the understanding of COVID-19 infections in children will help researchers to develop better treatments.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.